Abstract: Four carried mutations exclusively linked to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (K103N, K103N/S) and one carried mutations to both NNRTIs (G190S, K101E) and nucleoside reverse transcriptase inhibitors (NRTIs) (M184V).
Discussion: In Guinea Bissau, the most commonly used NNRTI is Efavirenz which is less effective in patients with the mutation K103N/S.
Discussion: The K103N/S mutation/s was found most frequently in this study and represents one of the most commonly
Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.
Abstract: In contrast, resistances to non-NRTIs (NNRTI, 4.7%) doubled between 2014 and 2016 from 3.2% to 6.4% (ptrend = 0.02) mainly due to the K103N mutation (from 1.7% to 4.1%; ptrend = 0.03) predominantly detected in recently infected German MSM not linked to transmission clusters.
Abstract: Reduced susceptibility to recommended first-line therapies was low with 1.0% for PIs, 1.3% for NRTIs and 0.7% for INSTIs, but high for the NNRTIs efavirence (4.9%) and rilpivirine (6.0%) due to the K103N mutation and the polymorphic mutation E138A.
Result: Among the `not cluster-linked sequences carrying the K103N mutation the d
Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Result: As expected, the number and type of mutations with frequencies > 20% (those within Sanger sequencing-based detection level) matched the cART history of the patient, e.g., the virus from patient SG28 had mutations associated with resistance to ABC (L74I 97.6% frequency), 3TC (M184V 99.7%), and EFV (K103N 98.8%, P225H 99.5%) and had been exposed to RTV, DRV, ABC, 3TC, and EFV; while patient SG86 had a virus with resistance to FTC (M184V 98.9%) and RAL (L74M 97.9%, E92Q 86.1% and T97A 99.8%) after being treated over the years with RTV, LPV, DRV, FTC, TDF, and RAL (Additional file 1: Table S1).
Result: Most of the minority mutations in viruses from both groups of naive patients were observed in the
Long-term virological outcome in children receiving first-line antiretroviral therapy.
Abstract: At the time of virologic failure, multiple NNRTI-associated mutations were observed: 80%-K103N and Y181C being the major NNRTI mutations-observed.
Result: K103N (48%), Y181C (37%), G190A/S (25%), Y188C/L (10%), Result: A retrospective DRM testing showed that only 6.4% (5/78) of the children had K103N as the major DRM at baseline (pre-ART).
Result: DRM results were available for 3 of these children at 12th month and they had either M184V or M184I mutation in addition to K103N at this time point.
Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
Abstract: The HIV genotype revealed Met184Val, Leu74Val, Leu100Ile, and Lys103Asn mutations in reverse transcriptase, and the phenotype showed susceptibility to tenofovir disoproxil fumarate and resistance to emtricitabine.
Result: Genotypic testing (GenoSure MG) for the HIV strain isolated from this patient showed notable RT mutations of L74V, L100I, M184V, and K103N, none of which are known to confer resistance to TDF, although M184V confers high-level resistance to FTC.
Result: SGS was consistent with the standard genotype in detecting RT mutations: specificall
HIV-1 subtype diversity, transmission networks and transmitted drug resistance amongst acute and early infected MSM populations from Coastal Kenya.
Abstract: The most prevalent TDR mutation was K103N (n = 5), with sequences forming transmission clusters of two and three taxa each.
Discussion: Indeed, all our observed K103N mutations formed two phylogenetically related transmission clusters spanning over several years, suggesting that they may have been in circulation for a while, and were unsuspectingly propagated onward in the community as new infections.
Discussion: Observed TDR mutations were non-complex, with a predominance of the common NNRTI-based K103N mutation.
Discussion: The high level of K103N mutation is consistent with literature from Kenya, and has been attributed to the widespread use of NNRTI in first line ART and the historic use of Nevirapine monotherapy in the prevention of mother to ch
Evaluation of Acquired HIV Drug Resistance among People Living with HIV Who Have Taken Antiretroviral Therapy for 9-15 Months in 14 Triangular Clinics in Iran, 2015-2016.
Abstract: The most frequently detected TDRMs were K103N (2.2%), T215 revertants (1.6%), M41L (0.9%) and L90M (0.7%).
Result: The most frequently detected mutations were T215 revertants (not F/Y) (268; 1.6%) and other TAMs [M41L (141; 0.9%) and K219Q/N (104; 0.6%)] conferring resistance to the NRTI drug class; K103N (354; 2.2%) and Y181C (66; 0.4%) conferring resistance to the NNRTI drug class, and L90M (111; 0.7%) and M46L (48; 0.3%) conferring resistance to the PI drug class.
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.
PMID: 27659733
2017
The Journal of antimicrobial chemotherapy
Abstract: K103N (48.9%) and V106M (34.9%) were the most common NNRTI mutations.
Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK.
PMID: 27742812
2017
The Journal of antimicrobial chemotherapy
Abstract: The most common mutations detected at >20% and 2%-20% mutation frequency differed for each drug class, these respectively being: L90M (n = 7) and M46IL (n = 10) for PIs; T215rev (n = 9) and D67GN (n = 4) for NRTIs; and K103N (n = 5) and G190E (n = 2) for NNRTIs.
HIV mutation literature information.
PMID: 
2018
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT